R-VK4-40 is a highly selective, potent and orally available dopamine D3 receptor (D3R) antagonist with Ki of 6.8 nM, >1500-dold selectivity over D2R.
R-VK4-40 dose-dependently inhibited oxycodone self-administration and shifted oxycodone dose-response curves downward, attenuated oxycodone reward and augments analgesia in rodents.
R-VK4-40 produced mild antinociceptive effects without altering open-field locomotion or rotarod locomotor performance.
R-VK4-40 produced mild antinociceptive effects without altering open-field locomotion or rotarod locomotor performance.
